Nonetheless, these inhibitors highlight the potential of GSK3β-targeted therapies to slow CKD progression by addressing core molecular drivers of kidney injury, underscoring the need for continued research into precise and effective therapeutic strategies for CKD. This evidence concerns the gene GSK3B and chronic kidney disease.